Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Poor clinical outcomes and immunoevasive contexture in gastric cancer patients bearing p16 high phenotype.

Cancer - 15 Mar 2026

Wang Jieti, Gu Yun, Zhang Ziqiu, Ling Zhen, Lin Chao, Liu Hao, Li Ruochen, He Hongyong, Shao Fei, Xu Jiejie

Abstract excerpt

BACKGROUND: The aberrant p16INK4a expression has been identified in gastric cancer (GC). However, the staining pattern of p16INK4a and its associations with clinical outcomes and immune contexture remains obscure. METHODS: This study involved two patient cohorts, the Zhongshan Hospital (ZSHS, n = 443) and Samsung Medical Center (SMC, n = 43) cohort. Patients were divided into p16INK4a loss, wild-type (WT), and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Biomarkers, Tumor
Share to Chemotherapy, Adjuvant

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclin-Dependent Kinase Inhibitor p16

Share to Immune Checkpoint Inhibitors

Share to Phenotype

Share to Prognosis

Share to Stomach Neoplasms

Source

Identifiers

PMID: 41831206
DOI: 10.1002/cncr.70363

Genes

GC
CCNE1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Poor clinical outcomes and immunoevasive contexture in gastric cancer patients bearing p16 high phenotype.PMID 41831206Read ↗

MUC4, MUC16, and TTN genes mutation correlated with prognosis, and predicted tumor mutation burden and immunotherapy efficacy in gastric cancer and pan‐cancerSemantic proximity Read ↗

Pathway Mutation Accumulate Perturbation Score: A prognostic and predictive biomarker for immunotherapy in advanced gastric cancer.Semantic proximity Read ↗

Clinicopathological Features of Epstein-Barr Virus Infection, Microsatellite Instability, Tumor Mutation Burden and PD-L1 Status in Chinese Patients with Gastric CancerSemantic proximity Read ↗

Somatic mutational profiles of stage II and III gastric cancer according to tumor microenvironment immune typeSemantic proximity Read ↗

Clinicopathological features of Epstein-Barr virus infection, microsatellite instability, tumor mutation burden and PD-L1 status in Chinese patients with gastric cancerSemantic proximity Read ↗

Influence of Tumor Mutational Burden on Immune-infiltrating Cells in Stomach AdenocarcinomaSemantic proximity Read ↗

A Novel Tumor Suppressor Gene, TMEM171, Inhibits the Development of Gastric Cancer by Dephosphorylating IKBα and Inactivating the NF-kB Signaling PathwaySemantic proximity Read ↗

Tumor mutation burden as a biomarker in resected gastric cancer via its association with immune infiltration and hypoxia.Semantic proximity Read ↗

Somatic ARID1A mutation stratifies patients with gastric cancer to PD-1 blockade and adjuvant chemotherapy.Semantic proximity Read ↗

Four distinct immune microenvironment subtypes in gastric adenocarcinoma with special reference to microsatellite instabilitySemantic proximity Read ↗

Clinicopathological and Molecular Differences Between Gastric-type Mucinous Carcinoma and Usual-type Endocervical Adenocarcinoma of the Uterine Cervix.Semantic proximity Read ↗

Impact of Age on Tumor Mutation Burden in Gastric patients:a secondary analysis based on a cross-sectional studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.